Literature DB >> 28700966

Utility of surveillance MRI in women with a personal history of breast cancer.

Audree Tadros1, Brittany Arditi2, Christina Weltz1, Elisa Port1, Laurie R Margolies3, Hank Schmidt4.   

Abstract

PURPOSE: To determine the utility and rate of biopsy in women with a positive history of breast cancer screened with MRI.
METHODS: Retrospective review of 491 breast MRI screening examinations in women with a personal history of breast cancer.
RESULTS: In total, 107 biopsies were performed, an average of 0.09 biopsies per person year. The positive predictive value for biopsies prompted by MRI findings was 0.24 (95% C.I. 0.10-0.38). Eight of the nine subsequent cancers were initially identified on screening MRI alone.
CONCLUSION: Surveillance MRI in breast cancer survivors may increase detection of subsequent cancers while increasing rate of biopsy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biopsy; Breast cancer; MRI; Screening

Mesh:

Year:  2017        PMID: 28700966     DOI: 10.1016/j.clinimag.2017.06.007

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  4 in total

1.  Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol.

Authors:  Amy N Melsaether; Eric Kim; Eralda Mema; James Babb; Sungheon Gene Kim
Journal:  Clin Imaging       Date:  2019-06-27       Impact factor: 1.605

Review 2.  Screening MRI in Women at Intermediate Breast Cancer Risk: An Update of the Recent Literature.

Authors:  Manisha Bahl
Journal:  J Breast Imaging       Date:  2022-05-08

Review 3.  Contrast-enhanced MRI for breast cancer screening.

Authors:  Ritse M Mann; Christiane K Kuhl; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2019-01-18       Impact factor: 4.813

4.  Feasibility of abbreviated magnetic resonance imaging (AB-MRI) screening in women with a personal history (PH) of breast cancer.

Authors:  Yeong Yi An; Sung Hun Kim; Bong Joo Kang; Young Jin Suh; Ye Won Jeon
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.